9 Me­ters Bio­phar­ma and Cara Ther­a­peu­tics tout mid-stage da­ta for gas­troin­testi­nal, pru­ri­tus stud­ies

While 9 Me­ters Bio­phar­ma is still floun­der­ing in the pen­ny stock mar­ket, the com­pa­ny is hop­ing the lat­est re­sults for its can­di­date to treat short bow­el syn­drome, or SBS, can put to­geth­er some pos­i­tive mo­men­tum.

The com­pa­ny to­day an­nounced pre­lim­i­nary topline re­sults from its Phase II VI­BRANT study. Its can­di­date, vurole­natide, is a long-act­ing GLP-1 re­cep­tor ag­o­nist in de­vel­op­ment for the treat­ment of adult pa­tients with SBS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.